PMGC Holdings (ELAB) Income from Continuing Operations (2022 - 2026)
PMGC Holdings (ELAB) posted Income from Continuing Operations of 6067284.0 for Q1 2026, down 126.15% sequentially from 2682805.0 in Q4 2025, and down 5547.52% YoY from 111377.0 in Q1 2025.
PMGC Holdings (ELAB) Income from Continuing Operations (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Income from Continuing Operations for 5 years, with the latest figure at 6067284.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 5547.52% year-over-year to 6067284.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12061287.0 (down 652.14% YoY) and the FY2025 annual result came in at 8353923.0, up 38.06% from the prior year.
- Income from Continuing Operations declined to 6067284.0 in Q1 2026 per ELAB's latest filing, from 2682805.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1114518032.0 in Q4 2022 and troughed at 469324000.0 in Q3 2022.
- A 5-year average of 23756851.47 and a median of 1556794.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations surged 233.59% in 2024, then plunged 5547.52% in 2026.
- Over 5 years, Income from Continuing Operations stood at 1114518032.0 in 2022, then sank by 100.1% to 1082497.0 in 2023, then soared by 233.59% to 1446143.0 in 2024, then sank by 285.51% to 2682805.0 in 2025, then slumped by 126.15% to 6067284.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 6067284.0, 2682805.0, and 3311196.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -4.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.07 Mn |
| Dec 31, 2025 | -2.68 Mn |
| Sep 30, 2025 | -3.31 Mn |
| Jun 30, 2025 | -2.00 |
| Mar 31, 2025 | 111,377.00 |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -1.87 Mn |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -270.32 Mn |
| Jun 30, 2023 | -1.06 Mn |
| Mar 31, 2023 | -843,918.00 |
| Dec 31, 2022 | 1.11 Bn |
| Sep 30, 2022 | -469.32 Mn |